Y428 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ³úÇϼöü Àü¿± È£¸£¸ó | Anterior pituitary [adenohypophyseal] hormons causing adverse effects in therapeutic use |
 |
Y429 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ¹× »ó¼¼ºÒ¸íÀÇ È£¸£¸ó ±æÇ×Á¦ | Other and unspecified hormone antagonists causing adverse effects in therapeutic use |
 |
Y43 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀÏÂ÷Àû Àü½ÅÁ¦Á¦ | Primarily systemic agents causing adverse effects in therapeutic use |
 |
Y430 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç׾˷¹¸£±â ¹× Ç×±¸ÅäÁ¦ | Antiallergic and antiemetic drugs causing adverse effects in therapeutic use |
 |
Y431 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç׾ϼº ´ë»ç¾ïÁ¦Á¦ | Antineoplastic antimetabolites causing adverse effects in therapeutic use |
 |
Y431 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â »çÀÌŸ¶óºó | Cytarabine causing adverse effects in therapeutic use |
 |
Y432 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç׾ϼº õ¿¬¹° | Antineoplastic natural products causing adverse effects in therapeutic use |
 |
Y433 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ Ç×¾ÏÁ¦ | Other antineoplastic drugs causing adverse effects in therapeutic use |
 |
Y433 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç׾ϼº Ç×»ýÁ¦ | Antineoplastic antibiotics causing adverse effects in therapeutic use |
 |
Y434 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¸é¿ª¾ïÁ¦Á¦ | Immunosuppressive agents causing adverse effects in therapeutic use |
 |
Y435 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â »ê¼ºÈÁ¦ ¹× ¾ËÄ®¸®ÈÁ¦ | Acidifying and alkalizing agents causing adverse effects in therapeutic use |
 |
Y436 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº È¿¼Ò·ù | Enzymes, NEC causing adverse effects in therapeutic use |
 |
Y438 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ±âŸ ÀÏÂ÷Àû Àü½ÅÁ¦Á¦ | Other primarily systemic agents, NEC causing adverse effects in therapeutic use |
 |
Y438 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Á߱ݼӱæÇ×Á¦ | Heavy-metal antagonists causing adverse effects in therapeutic use |
 |
Y439 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â »ó¼¼ºÒ¸íÀÇ ÀÏÂ÷Àû Àü½Å¾à¹° | Primarily systemic agent, unspecified causing adverse effects in therapeutic use |
 |
Y44 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀÏÂ÷ÀûÀ¸·Î Ç÷¾×¼ººÐ¿¡ ÀÛ¿ëÇÏ´Â Á¦Á¦ | Agents primarily affecting blood constituents causing adverse effects in therapeutic use |
 |
Y440 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â öÁ¦Á¦ ¹× ±âŸ Ç×ÀúÇ÷»ö¼Ò¼º ºóÇ÷Á¦Á¦ | Iron preparations and other anti-hypochromic-anemia preparations causing adverse effects in therapeutic use |
 |
Y441 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ºñŸ¹Î B12, ¿±»ê ¹× ±âŸ Ç×°Å´ëÀû¸ð±¸¼º ºóÇ÷ Á¦Á¦ | Vitamin B12, folic acid and other anti-megaloblastic-anemia preparations causing adverse effects in therapeutic use |
 |
Y442 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç×ÀÀ°íÁ¦ | Anticoagulants causing adverse effects in therapeutic use |
 |
Y443 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç×ÀÀ°í¼º ±æÇ×Á¦, ºñŸ¹Î K ¹× ±âŸ ÀÀ°íÁ¦ | Anticoagulant antagonists, vitamin K and other coagulants causing adverse effects in therapeutic use |
 |